Kankakee, Illinois will be the site of a major expansion of CSL’s manufacturing facility, announced March 9, 2026. The $1.5 billion investment is intended to increase production of life-sustaining, plasma-derived therapies and albumin, and will create at least 300 new jobs.
Expansion Details
The expansion builds on over $3 billion CSL has already invested in U.S. Operations since 2018. It will incorporate CSL’s Horizon 2 manufacturing process, a patented technology designed to increase the yield of immunoglobulin from plasma. The expanded facility is expected to be operational by 2031.
CSL CEO and Managing Director Gordon Naylor emphasized the importance of plasma donors, stating, “Behind every plasma-derived therapy is a person trying to live a more stable life, and donors who made that therapy possible.”
Economic Impact
Illinois Governor JB Pritzker hailed the investment as “a powerful vote of confidence in our state,” noting it will strengthen domestic supply chains for critical therapies. The Illinois Manufacturers’ Association stated the expansion is “a win for Illinois and the many people across the globe who rely on the groundbreaking work of CSL.”
The expansion is expected to benefit the Kankakee region through job creation and infrastructure improvements, according to Illinois State Senator Patrick Joyce.
Plasma-Derived Therapies
Plasma-derived therapies (PDTs) are used to treat a range of conditions, including rare diseases like hemophilia, primary immunodeficiency, and hereditary angioedema (HAE). They are likewise used in emergency situations, such as trauma and postpartum hemorrhage.
Frequently Asked Questions
What is the purpose of the Kankakee expansion?
The expansion is intended to increase CSL’s ability to produce life-sustaining, plasma-derived therapies and albumin.
When is the expanded facility expected to be operational?
The Kankakee expansion is expected to be operational by 2031.
How many jobs will the expansion create?
The expansion will create at least 300 new jobs.
As CSL moves forward with this significant investment, how might increased manufacturing capacity impact the availability and accessibility of these critical therapies for patients worldwide?
